- Esteller, M. Relevance of DNA methylation in the management of cancer.
The Lancet Oncology 4, 351-358 (2003).
- Toyooka, S., et al. Aberrant methylation of the CDH13 (H-cadherin) promoter region in colorectal cancers and adenomas. Cancer Research 62, 3382-3386 (2002).
- Zou, H.Z., et al. Detection of aberrant p16 methylation in the serum of colorectal cancer patients. Clin Cancer Res 8, 188-191 (2002).
- Ebert, M.P., et al. Hypermethylation of the TPEF/HPP1 gene in primary and metastatic colorectal cancers. Neoplasia (New York, N.Y 7, 771-778 (2005).
- American Cancer Society. Colorectal Cancer Facts & Figures Special Edition 2005. Atlanta: American Cancer Society, 2005.
- Davies, R.J., Miller, R. & Coleman, N. Colorectal cancer screening: prospects for molecular stool analysis. Nature reviews 5, 199-209 (2005).
- Walsh, J.M. & Terdiman, J.P. Colorectal cancer screening: scientific review. JAMA 289, 1288-1296 (2003).
- Cokkinides V, B.P., Siegel R, Ward EM, Thun MJ. Cancer Prevention & Early Detection Facts & Figures 2008. Atlanta, GA: American Cancer Society. (2007).
- Levin, B., et al. Screening and surveillance for the early detection of colorectal cancer and adenomatous Polyps, 2008: a joint guideline from the American Cancer Society, the US Multi-Society Task Force on Colorectal Cancer, and the American College of Radiology. CA: a cancer journal for clinicians 58, 130-160 (2008).
- Winawer, S.J. Screening sigmoidoscopy: can the road to colonoscopy be less traveled? Annals of Internal Medicine 139, 1034-1035 (2003).
- Widschwendter, M. & Jones, P.A. The potential prognostic, predictive, and therapeutic values of DNA methylation in cancer. Commentary re: J. Kwong et al., Promoter hypermethylation of multiple genes in nasopharyngeal carcinoma. Clin. Cancer Res., 8: 131-137, 2002, and H-Z. Zou et al., Detection of aberrant p16 methylation in the serum of colorectal cancer patients. Clin. Cancer Res., 8: 188-191, 2002. Clin Cancer Res 8, 17-21 (2002).
- Jones, P.A. & Laird, P.W. Cancer epigenetics comes of age. Nature Genetics 21, 163-167 (1999).
- Baylin, S.B., et al. Aberrant patterns of DNA methylation, chromatin formation and gene expression in cancer. Human molecular genetics 10, 687-692 (2001).
- Toyota, M., et al. Aberrant methylation of the Cyclooxygenase 2 CpG island in colorectal tumors. Cancer Research 60, 4044-4048 (2000).
- Eads, C.A., et al. MethyLight: a high-throughput assay to measure DNA methylation. Nucleic Acids Research 28, E32 (2000).
- Cottrell, S.E., et al. A real-time PCR assay for DNA-methylation using methylation-specific blockers. Nucleic acids research 32, e10 (2004).
- Lofton-Day, C., et al. DNA methylation biomarkers for blood-based colorectal cancer screening. Clinical Chemistry 54, 414-423 (2008).
- Model, F., et al. Identification and validation of colorectal neoplasia-specific methylation markers for accurate classification of disease. Mol Cancer Res 5, 153-163 (2007).
- Surka, M.C., Tsang, C.W. & Trimble, W.S. The mammalian septin MSF localizes with microtubules and is required for completion of cytokinesis. Molecular Biology of the Cell 13, 3532-3545 (2002).
- Osaka, M., Rowley, J.D. & Zeleznik-Le, N.J. MSF (MLL septin-like fusion), a fusion partner gene of MLL, in a therapy-related acute myeloid leukemia with a t(11;17)(q23;q25). Proceedings of the National Academy of Sciences of the United States of America 96, 6428-6433 (1999).
- Russell, S.E., et al. Isolation and mapping of a human septin gene to a region on chromosome 17q, commonly deleted in sporadic epithelial ovarian tumors. Cancer Research 60, 4729-4734 (2000).
- Burrows, J.F., et al. Altered expression of the septin gene, SEPT9, in ovarian neoplasia. The Journal of Pathology 201, 581-588 (2003).
- Kuhlenbaumer, G., et al. Mutations in SEPT9 cause hereditary neuralgic amyotrophy. Nature Genetics 37, 1044-1046 (2005).
- Lynch, H.T. & de la Chapelle, A. Hereditary colorectal cancer. The New England Journal of Medicine 348, 919-932 (2003).
- Rex, D.K., Lehman, G.A., Hawes, R.H., Ulbright, T.M. & Smith, J.J. Screening colonoscopy in asymptomatic average-risk persons with negative fecal occult blood tests. Gastroenterology 100, 64-67 (1991).
|
